دورية أكاديمية
أعرض في EDS

Fluoropyrimdine therapy induced alterations in interleukins expression in colorectal cancer patients.

التفاصيل البيبلوغرافية
العنوان: Fluoropyrimdine therapy induced alterations in interleukins expression in colorectal cancer patients.
المؤلفون: Fouad MA; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt., Salem SE; Medical Oncology Department, National Cancer Institute, Cairo, Egypt., Osman AS; Medical Pharmacology Department, Faculty of Medicine, Cairo University, Giza, Egypt., Badr DM; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt., Hussein MM; Medical Oncology Department, National Cancer Institute, Cairo, Egypt., Zekri AN; Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt., Hafez HF; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt., Kamel MM; Clinical Pathology Department, National Cancer Institute, Cairo, Egypt., Shouman SA; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt.
المصدر: International journal of immunopathology and pharmacology [Int J Immunopathol Pharmacol] 2021 Jan-Dec; Vol. 35, pp. 20587384211008332.
نوع المنشور: Controlled Clinical Trial; Journal Article
اللغة: English
بيانات الدورية: Publisher: Sage Publications Country of Publication: England NLM ID: 8911335 Publication Model: Print Cited Medium: Internet ISSN: 2058-7384 (Electronic) Linking ISSN: 03946320 NLM ISO Abbreviation: Int J Immunopathol Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : London : Sage Publications
Original Publication: [Chieti, Italy?] : Biomedical Research Press
مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Capecitabine/*pharmacology , Colorectal Neoplasms/*genetics , Interleukin-1beta/*genetics , Interleukin-6/*genetics , Oxaliplatin/*pharmacology, Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Capecitabine/therapeutic use ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/mortality ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Oxaliplatin/therapeutic use ; Young Adult
مستخلص: This study monitored the changes in the expression of inflammatory IL-6 and IL-1β during the treatment period of Fluoropyrimidine (FP) based therapy. RNA was extracted from the peripheral blood of 102 CRC patients before treatment with FP therapy, and from 48 and 32 patients after 3 and 6 months of treatment, respectively. The genetic transcription of IL-6 and IL-1β was determined by real time PCR. Patients were stratified according to their levels of IL-6 and IL-1β genes expression for subgroup and survival analyses. Baseline CRC patients showed overexpression of IL-6 and IL-1β compared to healthy control. FP therapy significantly induced IL-6 and IL-1β expression. Subgroup analysis showed that patients with right colon tumors had significant elevation in both IL-6 and IL-1β with FP therapy. FP therapy significantly induced IL-1β expression in patients ⩽45 years, smokers, with high baseline level of CA19.9, right colon tumors, low grade pathology, T3 tumors and positive lymph nodes. Survival analysis showed that baseline levels of interleukins expression had insignificant effect on overall survival and event free survival. FP therapy has an impact on the level of interleukins expression declared in certain clinicopathological subgroups of CRC patients, but without a prognostic significance on patients' survival.
References: Front Oncol. 2016 Apr 19;6:96. (PMID: 27148488)
Carcinogenesis. 2004 Nov;25(11):2247-55. (PMID: 15284182)
Eur J Cancer. 2010 May;46(7):1223-31. (PMID: 20335016)
World J Gastroenterol. 2019 Aug 21;25(31):4383-4404. (PMID: 31496619)
Immunity. 2019 Apr 16;50(4):778-795. (PMID: 30995499)
Front Pharmacol. 2018 Oct 18;9:1173. (PMID: 30405408)
Front Immunol. 2018 Jul 10;9:1578. (PMID: 30042763)
Int J Biol Sci. 2012;8(9):1248-53. (PMID: 23136553)
Oxid Med Cell Longev. 2020 Aug 13;2020:8032187. (PMID: 32855767)
Gastroenterology. 2010 Jun;138(6):2101-2114.e5. (PMID: 20420949)
Ecancermedicalscience. 2015 Apr 09;9:520. (PMID: 25932044)
Cancer Chemother Pharmacol. 2008 Apr;61(5):775-84. (PMID: 17624531)
Cancer Microenviron. 2015 Dec;8(3):187-200. (PMID: 26686225)
Gastroenterology. 2017 May;152(6):1434-1448.e15. (PMID: 28193514)
Neoplasia. 2018 Jul;20(7):721-733. (PMID: 29859426)
Cell Physiol Biochem. 2018;45(1):356-365. (PMID: 29402795)
Br J Pharmacol. 2000 Sep;131(1):152-9. (PMID: 10960082)
PLoS One. 2012;7(3):e31808. (PMID: 22412841)
Front Immunol. 2020 Aug 07;11:1526. (PMID: 32849517)
PLoS One. 2019 Jun 18;14(6):e0218604. (PMID: 31211804)
Curr Cancer Drug Targets. 2011 May;11(4):451-64. (PMID: 21247378)
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. (PMID: 29405201)
Ann Surg Oncol. 2000 Mar;7(2):133-8. (PMID: 10761792)
Anticancer Res. 2015 Apr;35(4):2235-40. (PMID: 25862884)
J Surg Oncol. 2003 Aug;83(4):222-6. (PMID: 12884234)
Br J Cancer. 2014 Jan 21;110(2):469-78. (PMID: 24346288)
World J Gastroenterol. 2011 Jul 14;17(26):3092-100. (PMID: 21912451)
Arch Biochem Biophys. 2016 Aug 15;604:20-6. (PMID: 27264420)
Mol Cancer. 2012 Nov 23;11:87. (PMID: 23174018)
Cancer. 2019 Jun 15;125(12):2002-2010. (PMID: 30854646)
Neoplasia. 2015 Mar;17(3):306-16. (PMID: 25810015)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Medicine (Baltimore). 2016 Jan;95(2):e2502. (PMID: 26765465)
Gastroenterology Res. 2018 Aug;11(4):264-273. (PMID: 30116425)
Neoplasia. 2014 Jan;16(1):31-42. (PMID: 24563618)
Semin Immunol. 2014 Feb;26(1):38-47. (PMID: 24602448)
Mol Oncol. 2019 Feb;13(2):109-131. (PMID: 30520562)
Drug Discov Today Dis Mech. 2011 Winter;8(3-4):e71-e78. (PMID: 22768019)
World J Gastroenterol. 2017 Mar 14;23(10):1780-1786. (PMID: 28348483)
Mucosal Immunol. 2014 Sep;7(5):1106-15. (PMID: 24424523)
فهرسة مساهمة: Keywords: colorectal cancer; fluoropyrimidine therapy; interleukins expression
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (IL1B protein, human)
0 (IL6 protein, human)
0 (Interleukin-1beta)
0 (Interleukin-6)
04ZR38536J (Oxaliplatin)
6804DJ8Z9U (Capecitabine)
تواريخ الأحداث: Date Created: 20210409 Date Completed: 20211118 Latest Revision: 20211118
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8040557
DOI: 10.1177/20587384211008332
PMID: 33832346
قاعدة البيانات: MEDLINE
الوصف
تدمد:2058-7384
DOI:10.1177/20587384211008332